Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P G Richardson

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Leukemia|October 24, 2013
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitorsT Hideshima, R Mazitschek, L Santo, et al.
Current Pharmaceutical Biotechnology|December 16, 2006
Bortezomib as an antitumor agentA M Roccaro, T Hideshima, P G Richardson, et al.
Leukemia|May 11, 2017
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survivalH Ohguchi, T Harada, M Sagawa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 3, 2018
Ixazomib-induced cutaneous necrotizing vasculitisA Alloo, H Khosravi, S R Granter, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 1, 2022
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert RoundtableA K Nooka, L J Costa, C J Gasparetto, et al.
Blood Cancer Journal|May 16, 2015
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myelomaT Hideshima, F Cottini, H Ohguchi, et al.
Leukemia|November 11, 2006
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsS Jagannath, P G Richardson, P Sonneveld, et al.
Leukemia|July 4, 2008
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myelomaI Breitkreutz, M S Raab, S Vallet, et al.
Leukemia|March 8, 2019
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Leukemia|September 11, 2009
The use of novel agents in the treatment of relapsed and refractory multiple myelomaJ P Laubach, A Mahindra, C S Mitsiades, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Leukemia|October 24, 2013
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitorsT Hideshima, R Mazitschek, L Santo, et al.
Current Pharmaceutical Biotechnology|December 16, 2006
Bortezomib as an antitumor agentA M Roccaro, T Hideshima, P G Richardson, et al.
Leukemia|May 11, 2017
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survivalH Ohguchi, T Harada, M Sagawa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 3, 2018
Ixazomib-induced cutaneous necrotizing vasculitisA Alloo, H Khosravi, S R Granter, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 1, 2022
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert RoundtableA K Nooka, L J Costa, C J Gasparetto, et al.
Blood Cancer Journal|May 16, 2015
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myelomaT Hideshima, F Cottini, H Ohguchi, et al.
Leukemia|November 11, 2006
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsS Jagannath, P G Richardson, P Sonneveld, et al.
Leukemia|July 4, 2008
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myelomaI Breitkreutz, M S Raab, S Vallet, et al.
Leukemia|March 8, 2019
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Leukemia|September 11, 2009
The use of novel agents in the treatment of relapsed and refractory multiple myelomaJ P Laubach, A Mahindra, C S Mitsiades, et al.
Pageof 6